Combining the biological risk factors, anti-ALK antibody titer and minimal disseminated disease, allowed the identification of pediatric NPM-ALK-positive ALCL patients with a very low risk of relapse [49]. This evidence concerns the gene ALK and anaplastic large cell lymphoma.